Completed PHASE3 INTERVENTIONAL 1-arm NCT00304356

Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection

Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Colitis in Patients Who Have Failed Conventional Therapy

Sponsor: Baylor College of Medicine

Conditions Clostridium Enterocolitis Pseudomembranous Colitis

Interventions Nitazoxanide

Updated 7 times since 2017 Last updated: May 8, 2017 Started: Jan 31, 2004 Primary completion: Jan 31, 2007 Completion: Jan 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Clostridium Enterocolitis and Pseudomembranous Colitis and is currently completed. Baylor College of Medicine leads this study, which shows 7 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Nov 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Nov 2021 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Dec 2017 — Jun 2018 [monthly]

Completed PHASE3

Status: Unknown Status → Completed
Jan 2017 — Dec 2017 [monthly]

Unknown Status PHASE3

First recorded

Jan 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Baylor College of Medicine
Daniel M. Musher MD

Data source: Michael E. DeBakey VA Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States